SYFa4f70fc8de8f4798ae931e6210806aafRegistry ID: 2023-505711-20-00|UnknownPhase 4Results
Loading search results
interventional
N/A
1 country
1
To evaluate the effect of secukinumab 150mg in reducing SNOT-22 and NPS scores for patients with CRSwNP) in treating non-type 2 CRSwNP
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 17, 2023
Actual (reported)mean change of NPS and SNOT-22 scores from baseline to week 16
mean change from baseline to week 16 in IL-17 associated inflammatory markers
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Cosentyx 150 mg solution for injection in pre-filled syringe
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Cosentyx 150 mg solution for injection in pre-filled syringe
Named ingredient: secukinumab
View registry recordTartu University Hospital
Tartu Linn, 50406, Estonia
Ear Clnic
First Submitted
May 17, 2023
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.